Topline data from Phase 3 REFOCUS-ALZ study of simufilam in patients with mild-to-moderate Alzheimer’s disease expected late ...

We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a ...

Macroeconomic factors have weighed on US stocks in the final days of the year, with the broader market declining by over 1% ...

Energy Beam Sciences, Inc. (“EBS”) announced that they have sold their tungsten filament product, manufacturing and associated assets to Ted Pella, Inc. (“TPI”). Michael Nesta, the owner and President ...

We recently compiled a list of the Jim Cramer Talked About These 8 Stocks. In this article, we are going to take a look at ...

The board of directors for Covington Life Sciences Partners Inc. has announced Christin Godale as its next executive director ...

What's on the horizon for the life sciences industry? Robin Johnson, PharmD, Gene Therapy Submissions Lead, inSeption Group What unique challenges do gene therapy submissions face compared to ...

We came across a bullish thesis on Gilead Sciences, Inc. (NASDAQ:GILD) on Substack by Magnus Ofstad. In this article, we will ...

NEW YORK, NY / ACCESSWIRE / January 4, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities ...

Cassava Sciences Inc (SAVA) stock saw a decline, ending the day at $2.4 which represents a decrease of $-0.10 or -4.00% from the prior close of $2.5. The stock opened at $2.44 and touched a low of $2.

In a world where aging gracefully is the ultimate goal for many, the quest for effective anti-aging solutions has led to ...

With a client base that includes the world's top 20 pharma companies, Indegene brings a strong track record of modernizing the industry with its deep domain expertise and life sciences-contextualized ...